VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $5.75 target price on the stock. HC Wainwright’s target price suggests a potential upside of 98.96% from the company’s previous close.

VYNE Therapeutics Trading Up 6.6 %

Shares of NASDAQ VYNE opened at $2.89 on Monday. VYNE Therapeutics has a 12-month low of $1.67 and a 12-month high of $8.73. The firm’s 50-day moving average price is $2.50 and its 200-day moving average price is $2.59. The stock has a market capitalization of $40.75 million, a price-to-earnings ratio of -0.41 and a beta of 1.26.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.30. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. On average, equities analysts predict that VYNE Therapeutics will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Eventide Asset Management LLC acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,394,336 shares of the company’s stock, valued at approximately $3,249,000. Eventide Asset Management LLC owned 9.99% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.